Definitive Healthcare Corp. (NASDAQ:DH) Given Average Recommendation of “Reduce” by Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has earned a consensus recommendation of “Reduce” from the ten brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $1.4714.

DH has been the topic of several analyst reports. Morgan Stanley dropped their target price on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. BTIG Research restated a “neutral” rating on shares of Definitive Healthcare in a report on Friday, September 4th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $1.00 price target on shares of Definitive Healthcare in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Monday, August 31st.

Institutional Investors Weigh In On Definitive Healthcare

A number of institutional investors have recently made changes to their positions in DH. Corient Private Wealth LP bought a new stake in shares of Definitive Healthcare during the second quarter valued at approximately $378,000. Squarepoint Ops LLC lifted its position in Definitive Healthcare by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock valued at $292,000 after acquiring an additional 111,634 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in Definitive Healthcare by 100.0% during the 4th quarter. Pinnacle Associates Ltd. now owns 260,012 shares of the company’s stock valued at $746,000 after purchasing an additional 130,012 shares during the last quarter. Williams & Novak LLC boosted its stake in Definitive Healthcare by 155.8% during the 2nd quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock valued at $65,000 after purchasing an additional 47,880 shares during the last quarter. Finally, Flywheel Private Wealth LLC bought a new stake in shares of Definitive Healthcare in the 1st quarter worth $83,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Price Performance

Shares of NASDAQ DH opened at $0.96 on Tuesday. Definitive Healthcare has a fifty-two week low of $0.61 and a fifty-two week high of $4.35. The company has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $0.90. The company has a market capitalization of $102.48 million, a price-to-earnings ratio of -0.60, a P/E/G ratio of 11.85 and a beta of 1.40. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. The firm had revenue of $55.20 million for the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Analysts expect that Definitive Healthcare will post 0.06 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp. (NASDAQ: DH) provides commercial intelligence and data analytics solutions for the healthcare industry. Its platform is designed to help organizations identify and understand healthcare providers, institutions, markets and patient populations, supporting decisions related to sales, marketing, market access, strategy and business development.

The company’s products and services include healthcare provider and facility data, claims-based insights, organizational and affiliation information, analytics tools, workflow solutions and intelligence related to clinical trials and healthcare markets.